UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029113
Receipt number R000033293
Scientific Title Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis
Date of disclosure of the study information 2017/09/20
Last modified on 2019/03/17 09:49:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis

Acronym

Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis

Scientific Title

Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis

Scientific Title:Acronym

Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis

Region

Japan


Condition

Condition

Patients with interstitial cystitis

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To study beneficial effect of fermented buckwheat sprouts on patients with interstitial cystitis

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Primary outcomes are clinical questionnaire test (subjective symptom for OABSS, IPSS, bother OABSS,et) and maximal urine before and after repeated oral intake (12 weeks) of fermented buckwheat sprouts

Key secondary outcomes

Key secondary outcomes are the following examinations:
1)height, body weight
2)Questionnaire for subjective symptoms for overactive bladder, prostatic hyperplasia, lower urinary tract symptoms and interstitial cystitis, and urination
3)physical examination
4)hematology test
5)quantitative measurements of various clinical biomarkers in the blood and urine.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking

NO

Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Ingestion of test food including fermented buckwheat sprouts (12 weeks, 4 tablets / once a day)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients with interstitial cystitis who exert either pollakiuria, acceleration of urinary desire or urinary urgency in addition to bladder pain
2) Patients who have received confirmed diagnosis of interstitial cystitis by the cystoscopy or hydrostatic dilator in the past.
3) Patients who are not satisfied by the current treatment

Key exclusion criteria

1) Patients with a previous history of urinary tract and genital infection within the past 3 months (excluding asymptomatic pyuria).
2) Patients within 3 months after hydrostatic dilator.
3) Patients with an interstitial cystitis symptom score of less than 9 ( a perfect score of 20) and satisfying the current treatment at more than 50 scores of VAS
4) Patients who have taken in fermented buckwheat sprouts within the past 3 months
5) Patients whose major cause of current symptoms (having bladder pain and frequent urination, urinary acceleration or urinary urgency) may be considered as other diseases (overactive bladder, neurogenic bladder, prostatic hyperplasia etc.)
6) The subjects who have allergy symptoms by buckwheat (test ingredients)
7) The subjects who are judged to be inappropriate by the responsible doctor.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Shizuo
Middle name
Last name Yamada

Organization

University of Shizuoka

Division name

Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences

Zip code

422-8526

Address

52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan

TEL

054-264-5625

Email

yamada@u-shizuoka-ken.ac.jp


Public contact

Name of contact person

1st name Shizuo
Middle name
Last name Yamada

Organization

University of Shizuoka

Division name

Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences

Zip code

422-8526

Address

52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan

TEL

054-264-5625

Homepage URL


Email

yamada@u-shizuoka-ken.ac.jp


Sponsor or person

Institute

Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka

Institute

Department

Personal name



Funding Source

Organization

Fujikogei Co. Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Kageyama Hospital (Shizuoka city)
Nakamura Hospital (Beppu city)

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka

Address

52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan

Tel

054-264-5625

Email

yamada@u-shizuoka-ken.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

静岡県立大学 薬食生命科学総合学府 薬学研究院 薬食研究推進センター


Other administrative information

Date of disclosure of the study information

2017 Year 09 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 08 Month 18 Day

Date of IRB

2017 Year 08 Month 18 Day

Anticipated trial start date

2017 Year 10 Month 10 Day

Last follow-up date

2018 Year 05 Month 07 Day

Date of closure to data entry

2018 Year 05 Month 15 Day

Date trial data considered complete

2018 Year 05 Month 15 Day

Date analysis concluded

2018 Year 05 Month 28 Day


Other

Other related information



Management information

Registered date

2017 Year 09 Month 12 Day

Last modified on

2019 Year 03 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033293


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name